Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with SHP2, such as cancer, lack effective and selective inhibitors that target this protein, which is crucial for signaling pathways involved in proliferation and immune responses.
Innovation Solution
Development of novel pyrazolo[3,4-b]pyrazine derivatives that selectively inhibit SHP2, offering anticancer activity by blocking its activation and downstream signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for SHP2-associated diseases, then existing therapeutic options are available, but effective and selective SHP2 inhibitors are lacking
Solution Approach 1:
The patent employs parameter changes by systematically varying chemical substituents (R1-R10 groups) on the pyrazolo[3,4-b]pyrazine core structure to optimize SHP2 binding affinity and selectivity. Different halogen, alkyl, and heterocyclic substitutions allow fine-tuning of the compound's interaction with the SHP2 active site while maintaining structural diversity for drug development
Solution Approach 2:
The invention creates composite molecular structures by combining the pyrazolo[3,4-b]pyrazine scaffold with various heterocyclic rings (pyridine, pyrimidine, triazine) and substituent groups. This composite approach allows the molecule to simultaneously engage multiple interaction points with SHP2, enhancing both potency and selectivity through multi-modal binding
2Productivity
If SHP2 is inhibited to block proliferation signaling, then anticancer activity is achieved, but side effects may occur
Solution Approach 1:
The patent applies local quality by designing substituents that specifically target the SHP2 binding pocket's unique structural features. The heterocyclic rings and positioned alkyl/halogen groups create localized interactions with specific residues in the SHP2 active site, ensuring that inhibition is focused on SHP2 rather than other phosphatases, thereby reducing off-target side effects while maintaining anticancer efficacy
Data Source
AI summary
The invention provides new pyrazine derivatives of formula (I):or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.